Nia Therapeutics

Focus: Nia Therapeutics is a Boston-based biotech focused on neural interfaces for memory restoration, operating in neurology and infectious diseases with early-stage pipeline programs.

Neurology Infectious Diseases

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Nia Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Nia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

High touch multi-pronged behavioral intervention

COVID-19 Vaccines

N/A

Clinical Trials (1)

NCT04732819Improving COVID-19 Vaccine Uptake in Nursing Homes

N/A

Help build intelligence for Nia Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering neural interface technology targeting high-unmet-need Alzheimer's disease with multiple Phase 1–2 programs in active development
Boston location provides access to leading academic medical centers and neurology research hubs
Early-stage opportunity to contribute to novel memory restoration modality before major inflection points

Watch Out For

Zero current job openings and no disclosed employee count suggest minimal active hiring or possible early-stage scaling challenges
Pipeline shows inconsistent therapeutic area focus (Alzheimer's, COVID-19 vaccines, HIV, dermatology) raising questions about strategy coherence and resource allocation
No disclosed funding, revenue, or financial data creates uncertainty about runway, cash position, and long-term viability

Generated by Claude from Nia Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BMS-984923

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT05804383A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Phase 1

BMS-984923

Drug Drug Interaction (DDI)

Phase 1

Clinical Trials (1)

NCT06632990A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Phase 1